Table 3 Additional variants from sequential rounds of conditioning.

From: Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Phenotype (primary variant)

Round

Variant

hg19 chr 6 position

Distance (bp) from primary variant^

p

pcorr*

ADA positive (AA_DRB1_120_32657518_N)

 

1

rs3093664

31544641

1004898

1.16E−06

 < 0.001

 

2

rs3130215

31525911

1023628

2.54E−06

 < 0.001

 

3

rs9268500

32376516

173023

5.46E−06

 < 0.001

 

4

rs9268543

32384800

164739

1.11E−08

 < 0.001

 

5

rs9469069

31866417

683122

4.64E−05

 < 0.001

 

6

rs3763313

32376470

173069

1.49E−04

0.001

 

7

rs3130062

31525911

1023628

1.01E−03

0.006

 

8

rs29220

29589665

2959874

1.08E−03

0.010

 

9

rs2267635

29592430

2957109

5.86E−04

0.013

 

10

rs4713420

30993566

1555973

2.40E−03

0.029

ADA max titer (rs7756741)

 

1

AA_DRB1_13_32660109_FG

32552130

31067

4.69E−05

0.002

 

2

rs2523453

31368124

1215073

1.49E−05

0.002

 

3

rs17496549

32409707

173490

4.92E−04

0.007

 

4

AA_C_9_31347600_S

31239620

1343577

9.42E−04

0.015

 

5

rs2240804

30920889

1662308

1.93E−03

0.041

 

6

rs3763355

32786881

− 203684

2.48E−03

0.056

 

7

rs2395171

32394536

188661

3.01E−03

0.093

  1. *p value corrected for multiple testing from 1000 iterations of resampling (Methods). ^positive values are 5' direction, negative are 3'.